Truffle Capital
Also known as Truffle Capital SAS, Truffle
Paris VC founded in 2001 by Philippe Pouletty and Bernard-Louis Roques; creates and finances BioMedTech companies (Abivax, Carvolix) and leads €5–15M fintech rounds.
- HEADQUARTERS
- Paris, France
- FOUNDED
- 2001
- AUM
- —
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 10 people
Focus
- STAGES
- SeedSeries ASeries B
- ASSET MIX
- Venture capital
- GEOGRAPHY
- Europe
Overview
Truffle Capital is an independent Paris venture capital firm founded in 2001 by Philippe Pouletty, Bernard-Louis Roques and Henri Moulard, and an AMF-approved portfolio management company. It works in two fields: BioMedTech (medtech and biotech), where it systematically acts as founder of companies such as Abivax and Carvolix, and fintech and insurtech, where since 2015 it has led rounds of €5–15M in companies with around €5M of recurring revenue. It says it has raised more than €1.2bn since creation, with 28 active portfolio companies, 46 exits and 15 IPOs.
PORTFOLIO (12)
- AbivaxNOTABLEBiotech & Life Sciences · IPO
- CarvolixHealthTech · since 2026
- CarbiosClimate & Energy · IPO
- CarmatHealthTech · IPO
- SymetisHealthTech · Acquired
- VeximHealthTech · Acquired
- Evexta BioBiotech & Life Sciences
- SpikImmBiotech & Life Sciences
- HydrosatSpace
- WydenFintech
- KOVRRFintech
- BridgeFintech
People
- Philippe PoulettyCEO & Co-Founder (BioMedTech) · source
- Bernard-Louis RoquesCEO & Co-Founder (Fintech) · source
- Henri MoulardChairman & Co-Founder · source
- Olivier HuonChief Financial Officer · source
- Antoine PauSenior Partner, BioMedTech · source
- Alain ChevallierSenior Partner, BioMedTech · source
- François RomaneixSenior Partner, BioMedTech · source
- Bozena AdamczykPartner, Fintech · source
- Alexis Le PortzPartner, Fintech · source
- Fanny BrugièreDirector of Investor Relations · source
Links
Frequently asked questions
Truffle Capital is a VC fund based in Paris, France, founded in 2001.
Yes. Truffle Capital invests its own capital in private companies.
Truffle Capital invests at Seed, Series A and Series B stages in HealthTech, Biotech & Life Sciences, Fintech and Artificial Intelligence.
Truffle Capital's stated ticket size is €5M–€15M.
Key people at Truffle Capital include Philippe Pouletty (CEO & Co-Founder (BioMedTech)), Bernard-Louis Roques (CEO & Co-Founder (Fintech)), Henri Moulard (Chairman & Co-Founder) and Olivier Huon (Chief Financial Officer).
Truffle Capital's investments include Abivax, Carvolix, Carbios, Carmat, Symetis, Vexim, Evexta Bio and SpikImm, among others.
The most recent publicly reported investment by Truffle Capital is Carvolix (€10M tranche (with Edwards Lifesciences)), announced in Jun 2026.
Yes. Truffle Capital manages capital from outside investors.